Literature DB >> 18990130

Hereditary episodic ataxias.

Joanna C Jen1.   

Abstract

Hereditary episodic ataxia (EA) syndromes are rare monogenic disorders that are phenotypically and genetically heterogeneous. The number of identified EA phenotypes is expanding. So far, mutations have been identified in four genes, all coding for membrane proteins including ion channels and transporters. The study of EA has illuminated previously unrecognized but important roles of ion channels and transporters in cerebellar function. This review summarizes recent advances and focuses on practical approaches in the diagnosis and treatment of episodic ataxia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18990130     DOI: 10.1196/annals.1444.016

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  14 in total

Review 1.  Recent advances in the genetics of cerebellar ataxias.

Authors:  Anna Sailer; Henry Houlden
Journal:  Curr Neurol Neurosci Rep       Date:  2012-06       Impact factor: 5.081

Review 2.  Update on the Pharmacotherapy of Cerebellar Ataxia and Nystagmus.

Authors:  Katharina Feil; Tatiana Bremova; Carolin Muth; Roman Schniepp; Julian Teufel; Michael Strupp
Journal:  Cerebellum       Date:  2016-02       Impact factor: 3.847

3.  A novel mutation in SLC1A3 causes episodic ataxia.

Authors:  Kazuhiro Iwama; Aya Iwata; Masaaki Shiina; Satomi Mitsuhashi; Satoko Miyatake; Atsushi Takata; Noriko Miyake; Kazuhiro Ogata; Shuichi Ito; Takeshi Mizuguchi; Naomichi Matsumoto
Journal:  J Hum Genet       Date:  2017-12-05       Impact factor: 3.172

Review 4.  Consensus Paper: Revisiting the Symptoms and Signs of Cerebellar Syndrome.

Authors:  Florian Bodranghien; Amy Bastian; Carlo Casali; Mark Hallett; Elan D Louis; Mario Manto; Peter Mariën; Dennis A Nowak; Jeremy D Schmahmann; Mariano Serrao; Katharina Marie Steiner; Michael Strupp; Caroline Tilikete; Dagmar Timmann; Kim van Dun
Journal:  Cerebellum       Date:  2016-06       Impact factor: 3.847

Review 5.  Aminopyridines for the treatment of neurologic disorders.

Authors:  Michael Strupp; Julian Teufel; Andreas Zwergal; Roman Schniepp; Kamran Khodakhah; Katharina Feil
Journal:  Neurol Clin Pract       Date:  2017-02

6.  Animal models of human cerebellar ataxias: a cornerstone for the therapies of the twenty-first century.

Authors:  Mario Manto; Daniele Marmolino
Journal:  Cerebellum       Date:  2009-09       Impact factor: 3.847

7.  Past, present and future therapeutics for cerebellar ataxias.

Authors:  D Marmolino; M Manto
Journal:  Curr Neuropharmacol       Date:  2010-03       Impact factor: 7.363

Review 8.  Physiologic alterations in ataxia: channeling changes into novel therapies.

Authors:  Vikram G Shakkottai; Henry L Paulson
Journal:  Arch Neurol       Date:  2009-10

Review 9.  Inborn errors of metabolism and motor disturbances in children.

Authors:  A García-Cazorla; N I Wolf; M Serrano; B Pérez-Dueñas; M Pineda; J Campistol; E Fernández-Alvarez; J Colomer; S DiMauro; G F Hoffmann
Journal:  J Inherit Metab Dis       Date:  2009-10       Impact factor: 4.982

Review 10.  Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond.

Authors:  Verena Isabell Leussink; Xavier Montalban; Hans-Peter Hartung
Journal:  CNS Drugs       Date:  2018-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.